Hansa Biopharma AB Stock Nasdaq Stockholm
Equities
SE0002148817
Biotechnology & Medical Research
Sales 2024 * | 239M 22M | Sales 2025 * | 343M 31.51M | Capitalization | 1.53B 141M |
---|---|---|---|---|---|
Net income 2024 * | -735M -67.59M | Net income 2025 * | -712M -65.48M | EV / Sales 2024 * | 8.4 x |
Net Debt 2024 * | 474M 43.59M | Net Debt 2025 * | 733M 67.44M | EV / Sales 2025 * | 6.62 x |
P/E ratio 2024 * |
-2.42
x | P/E ratio 2025 * |
-2.87
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anders Pedersen
BRD | Director/Board Member | 73 | 18-05-28 |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+47.81% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |